Clinical trials in malignancies where COX-2 expression correlates with poor prognosis (e.g., lung, breast, glioblastoma, pancreas, and colon) failed to show significant advantages for the use of NSAIDs or Coxibs in disease treatment.50 The gene discussed is PTGS2; the disease is glioblastoma.